# Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

> **NCT00672139** · PHASE4 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 156 (actual)

## Conditions studied

- Opioid-Induced Constipation

## Interventions

- **DRUG:** Methylnaltrexone bromide

## Key facts

- **NCT ID:** NCT00672139
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-05
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2018-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00672139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00672139, "Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00672139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*